CXCR1 and neoplasm: engineered interleukin 8 (IL‐8) receptors CXCR1 or CXCR2 in αvβ6‐targeted CAR T‐cells and demonstrated the superior anti‐tumour activity of these armed CAR‐T cells against established αvβ6‐expressing ovarian or pancreatic tumour xenografts.18